Proposal of a new classification system for complete mesocolic excison in right-sided colon cancer.
S Benz, A Tannapfel, Y Tam...
https://pubmed.ncbi.nlm.nih.gov/30838463/Actively Recruiting
Led by University of Turin, Italy · Updated on 2022-11-14
416
Participants Needed
14
Research Sites
N/A
Total Duration
Researchers are evaluating a surgical approach called Complete Mesocolic Excision with Central Vascular Ligation CMECVL compared to standard right hemicolectomy in patients with malignant tumors located in the right or proximal transverse colon. This Italian randomized controlled trial focuses on patients with stage II-IV colon cancer and aims to determine differences in disease-free survival as the primary outcome. The study also looks at safety, oncologic results, surgical quality, and quality of life as secondary outcomes. Participants will be randomly assigned to one of two groups one undergoing the conventional non-CME right hemicolectomy and the other receiving the CMECVL procedure. The CMECVL technique involves removing lymphovascular tissue at the origin of supplying vessels and preserving the mesocolon as an intact envelope. Various surgical approaches, including open, laparoscopic, or robotic surgery, are allowed. Surgeons decide the type of anastomosis and drain placement. The trial plans to enroll 416 patients over one and a half years, with five years of postoperative follow-up. During the study, patients will be monitored at 1, 4, 12, 24, 36, and 60 months after surgery. Researchers will collect demographic, baseline, perioperative, and postoperative data, evaluating outcomes such as disease-free survival at three years, safety measures including operative time and complications, overall survival, and quality of life. The total study duration is expected to be six and a half years, providing both short- and long-term information on these surgical methods.
CONDITIONS
Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer
M
Mario Solej, MD
H
Hogla Aridai Resendiz Aguilar, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Turin, Italy
Lead Sponsor
Federico II University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Surgical procedure and hospital stay up to 30 days post-operation
Participants undergo either the Complete Mesocolic Excision with Central Vascular Ligation (CME+CVL) or the conventional right hemicolectomy surgery for right colon cancer. This stage includes the surgery itself and immediate recovery care.
1 surgical hospitalization and approximately 1 month of post-operative care visits
Duration - Up to 5 years post-surgery
Participants are monitored for complications and recovery after surgery with scheduled follow-up visits to assess safety, oncologic outcomes, and quality of life.
Follow-up visits at 1, 4, 12, 24, 36, and 60 months post-operation
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
S Benz, A Tannapfel, Y Tam...
https://pubmed.ncbi.nlm.nih.gov/30838463/C A Bertelsen, B Bols, P Ingeholm...
https://pubmed.ncbi.nlm.nih.gov/20969719/Gennaro Galizia, Eva Lieto, Ferdinando De Vita...
https://pubmed.ncbi.nlm.nih.gov/23982425/Nam Kyu Kim, Young Wan Kim, Yoon Dae Han...
https://pubmed.ncbi.nlm.nih.gov/27566031/Maurizio Degiuli, Aridai H Resendiz Aguilar, Mario Solej...
https://pubmed.ncbi.nlm.nih.gov/38087139/Claus Anders Bertelsen
https://pubmed.ncbi.nlm.nih.gov/28157065/Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram...
https://pubmed.ncbi.nlm.nih.gov/30207593/Nicholas P West, Hirotoshi Kobayashi, Keiichi Takahashi...
https://pubmed.ncbi.nlm.nih.gov/22473170/Paul M Johnson, Geoff A Porter, Rocco Ricciardi...
https://pubmed.ncbi.nlm.nih.gov/16877723/University of Turin, Italy
Lead Sponsor
Federico II University
Collaborating Sponsor